Omalizumab: A novel therapy for allergic asthma

Annals of Pharmacotherapy

Volumn 38, Issue 7-8, 2004, Pages 1236-1242

  Davis, Lorrie A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Allergic asthma; Omalizumab; Xolair

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; OMALIZUMAB;

ALLERGIC ASTHMA; ANAPHYLAXIS; BASOPHIL; BREAST TUMOR; BURNING SENSATION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HEADACHE; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION PAIN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; PAROTID GLAND TUMOR; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; PROSTATE TUMOR; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT; SINUSITIS; SKIN TUMOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS; HUMANS; QUALITY OF LIFE;

EID: 3042601416     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D626     Document Type: Review

References (23)

1. American Lung Association, Epidemiology and Statistics Unit Research and Scientific Affairs. Trends in Asthma Morbidity and Mortality (March 2003). www.lungusa.org/data/asthma/asthma1.pdf (accessed 2003 Nov 7).
2. Centers for Disease Control and Prevention, National Center for Health Statistics. Fast stats A to Z: asthma. www.cdc.gov/nchsfastats/asthma. htm (accessed 2003 Nov 7).
3. National Asthma Education and Prevention Program, Expert Panel report. Guidelines for the diagnosis and management of asthma - update on selected topics 2002. NIH Publication no. 02-5075. Bethesda, MD: US Department of Health and Human Services, July 2002.
4. Corticosteroids. In: Sweetman SC, ed. Martindale: the complete drug reference. 33rd ed. Grayslake, IL: Pharmaceutical Press, 2002:1039-81.
5. Package insert. Xolair (omalizumab). East Hanover, NJ: Aventis, June 2003.
6. Kelly HW, Sorkness CA. Asthma. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 5th ed. New York: McGraw-Hill, 2002:475-510.
7. Abbas AK, Lichtman AH, eds. Basic immunology. Philadelphia: WB Saunders, 2001.
8. Easthope S, Jarvis B. Omalizumab. Drugs 2001;61:253-60.
9. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-45.
10. Fahy JV, Fleming E, Wong HH, Liu JT, Su JQ, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
11. Boulet LP, Chapman KR, Côté J, Kalra S, Bhagat R, Swystun VA, et al. Inhibitory effects of anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:1835-40.
12. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90.
13. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154-9.
14. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61.
15. Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O, et al. Omalizumab provides long-term control in patients with moderate to severe allergic asthma. Eur Respir J 2002;20:73-8.
16. Finn A, Gross G, Bavel J, Lee T, Windom H, Everhard F, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111:278-84.
17. Buhl R, Hanf G, Solèr M, Bensch G, Wolfe J, Everhard F, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20:1088-94.
18. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-7.
19. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003;131:46-52.
20. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;1085:E36.
21. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003;91:182-8.
22. Lemanske RF Jr, Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 2002;110:E55.
23. Omalizumab (Xolair): an anti-IgE antibody for asthma. Med Lett Drugs Ther 2003;45:67-8.